2020-06-30 08:00
Biovica’s annual report for the fiscal year 2019/2020 is published on our website https://biovica.com/investor-relations/financials/ Contact Anders Rylander, CEO Phone: +46-18-444 48 35 E-mail: anders.rylander@biovica.com Cecilia Driving, EVP CFO/HR/IR...
2020-06-17 08:00
Biovica, active in cancer diagnostics, today announced that the analytical validation of the blood test DiviTum has been completed. The validation aims to verify technical and precision requirements defined in consultation with the US Food and Drug Administration...
2020-06-05 08:00
Preparations for the launch of DiviTum® have started Significant events during the fourth quarter Significant events after the end of the period CEO’s comments Biovica has had yet another eventful quarter. We have focused our efforts on the...
2020-05-22 09:45
Uppsala, Sweden, May 22, 2020. The ASCO educational book 2020 highlights DiviTum® as a solution to address unmet needs within monitoring treatment effect of CDK4/6 inhibitors. The authors Erik S. Knudsen, PhD at Roswell Park Cancer Center, Geoffrey...
2020-05-11 08:15
Uppsala, Sweden, May 11, 2020. The scientific journals British Journal of Cancer, a Nature journal, and Biomarkers in Medicine have published articles on DiviTum® results and TK activity as a biomarker for evaluating efficacy of CDK4/6 inhibitors...
2020-05-11 08:00
Uppsala, Sweden, May 11, 2020. Biovica, active in cancer diagnostics, hosts today its virtual capital market day at 14.00-16.00. The purpose is to provide an update on Biovica's market launch strategy and goals. Biovica is also providing a market...
2020-05-06 10:25
Biovica, active in cancer diagnostics, will host a virtual Capital Markets Day on Monday 11 May from 14:00 to 16:00. Biovica is nearing market launch of DiviTum® in the US for the monitoring of metastatic breast cancer treatments. DiviTum® is...
2020-04-29 11:38
Biovica is nearing market launch of DiviTum® in the US for the monitoring of metastatic breast cancer treatments. DiviTum® is already being sold for research purposes, primarily to major pharmaceutical companies for use in clinical studies. After...
2020-04-08 08:00
The main purpose of including DiviTum® in studies performed at Mayo Clinic is to evaluate the changes in serum thymidine kinase activity, measured by DiviTum®, in patients with hormone positive metastatic breast cancer treated with today’s...
2020-03-25 08:30
“As DiviTum® is approaching commercialization we are strengthening the team. Robert brings insights from cancer diagnostics as well as therapeutics and has an excellent track record of successful product launches which will be valuable when...
>4,500
Numbers of patients in studies
28
Publications
32
Pharma Projects